JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - ALLOGENE THERAPEUTICS INC
Welcome, everyone, to 2026 Jeffries Global Healthcare Conference in London. My name is Roger Song, senior and covers make-up biotech in the U.S. It is my pleasure to have the five-side chair with Allogene Therapeutics, and we have CEO, Zach Roberts. Welcome, Zach. Thank you, Roger. Great to be here. Thanks for the opportunity. Awesome. All right, Zach, I want you to open up with some high-level overview of Allogene. We know you have a lot of exciting things already happened, and then also in the future. Thank you. Yeah, so Allogene is an allogeneic cell therapy company. We're developing CAR T-cells for patients with post-frontline large B-cell lymphoma using a very novel strategy in which we're treating patients who appear to be in a clinical remission but remain positive for minimal residual disease. That's our lead program. It's a pivotal study. It's called Alpha-3. And then we also have a very exciting and differentiated program in autoimmune disease in which we are using a novel product designed specifically for this indication set that is the world's first dual-targeting CAR-T CD19, CD70, also, of course, healthy donor-derived allogeneic product. Okay, great. Those are the two major topics we can touch today. So for C-MASEL, this Office 3, I think you have an interim analysis building, and then potentially going to be made next year. So give us a little bit more teaser, so what exactly you're going to see, and then what kind of statistics, the numbers you are targeting. Yeah, so the study's been open for a couple of years now. I would say that we have had a very nice year so far in 2026 for enrollment. We released some data back in April of this year. It was a pre-planned interim analysis in which we looked at efficacy as measured by MRD clearance. So as a reminder, everybody who comes into the Alpha-3 study is MRD positive. And so the patients were examined in the two arms. Observation is the control arm versus treatment with semicells is the experimental arm. And we looked at both safety and efficacy, and the efficacy there was assessed by the rate of MRD clearance. And we saw a very nice differential between the two arm. Fifty-eight percent of the patients in the semicell arm went from MRD positive to MRD negative, and only 16% of the patients in the control arm went from MRD positive to MRD negative. We had an extremely clean safety profile, no cases of CRS, no case of ICANS. Everybody was managed as an outpatient, including in community practices where CAR T is not generally given, no TOSI, no steroids. So this has really, I think, validated the hypothesis of alpha-3. The next analysis that is planned for the study is the one that you mentioned that was currently assumed to occur middle of 2027. That is looking not at MRD clearance, but at event-free survival, which is the primary endpoint of the study. And then we have the primary analysis that is scheduled for 2028. We assume it will happen in 2028, both are event-driven. So for this upcoming potential analysis next year, we haven't gone into much detail about the number of events or the alpha allocation between these two analyses, aside to say that a relatively small amount of alpha is allocated for that because we wanted to preserve most of the alpha for the primary analysis. So as we are conducting the study and executing, really our focus is on running a very clean study, one that is not affected by any kind of bias or that would impact the integrity or the data interpretability, because ultimately we believe that this will be a positive study when it's all said and done, and we believe it will also lead to the approval of semacell. So the most important thing from our perspective is just making sure that that data set, when it is finally generated, is a BLA quality and we will have a favorable outcome with the FDA. Yeah, absolutely. You know, was really interested in those details, but not necessarily, you know, you sometimes that you now need to disclose because, you know, you may change the trial integrity. So maybe just on the potential outcome, right, so, you Know, if the DSMB look at the data and then what would be the recommendations and how are you going to disclose the outcome to the stream? Yeah, so you brought up the Data Safety Monitoring Board. This is a DSMB-governed trial. It has a randomized pivotal study. So they will be the ones to conduct the analysis at the time of the event trigger, and they will being unblinded to the results. We'll only know how many events have accrued. We won't know in which arm. So when we hit the number of events that we're targeting and we submit the data to the DSMB, they'll evaluate the data. And there are sort of three main possibilities. One, in our view, the most likely possibility is that they will tell us that the study is on track and we should continue on to the primary analysis as planned. There is a chance that they could come back and say it's statistically significantly positive. And then they may, depending on what they see, they could make a recommendation that we stop the study and open it for efficacy and release the results. And then, of course, there's always a remote chance that they tell us that it's futile. Now, we don't expect, based on the early data, that that is a likely outcome, but in the spirit of completeness, that is something else that they could say. Got it. For the second outcome, which probably is the most interesting and optimistic outcome, if they think that the result hits statistics, You say it also depends on the magnitude of the result or the effect size. You will decide to unblind, and then also that unblinding means you can talk with the FDA, maybe potential file based on that interim result, because this is a pivotal study. If you unblind and what that means to the overall filing strategy. Yeah, so it's a great question, and it's one that we get asked about a lot. And so if the recommendation is to unblind the study effectively, that will be the sum total of the data that we have to communicate with the FDA. Because once the results of that study are known, it's going to be very difficult to get patients to randomize into a study where they have a 50% chance of ending up in the control arm, which they may have just learned from a press release, has worse outcomes, right? That's right. And additionally, patients who were already enrolled but had not yet experienced disease progression, when they find out that they're in the control arm and they would have done better if they were in the treatment arm, they may, you know, call their oncologist and say, I'd like to receive some treatment, right? So that does put us in a position where if that is statistically significant, you know, it needs to be a registrational package on its own because we won't be able to expect much data after that. Got it. Okay, so that without need to be strong enough, you think it can be registrational? Correct. Okay, got it. All right, and then so in terms of the measures, just remind us, what is the study design for the hazard ratio? And then have you disclosed the total EFS events need to not be the interim? So we haven't said anything about the number of events at either the interim or the primary. We have disclosed that the study is designed and powered to demonstrate a difference of a hazard ratio of 0.5. So that's essentially a doubling of EFS in the treatment arm relative to control. Got it. What I tried to get at is in order for insurance to hit statistics, it needs to be hazard ratio needs to be very high because the alpha span is low. Correct. And if your primary is 0.50, it doesn't need to be 0.20. Certainly to maintain a power that people would expect. So that is exactly right, Roger. It needs to be overwhelmingly positive. Overwhelmingly positive. Okay, got it. And then understanding you are not getting access to any of the data, but have you seen any blind data in the relatively regular base, and particularly for the safety dropouts, and anything you can say at this point? Well, I mean, safety is always monitored in real time in all of these trials, so if there are significant events in any of our programs, We know about that right away, usually within 24 hours. I will say that that has not happened in Alpha 3, and the safety data that we shared back in April at the interim analysis is consistent with what we've seen in the months that have followed. We are only looking at data at the time of pre-specified analysis, so there's no additional efficacy data or anything that I have access to. Yeah, sure. Okay. Recently, Epicor, the bispecifics plus RCHOP reported a pretty interesting hazard ratio in the first line, LBL, LCBL. So how do you think about the MRD positive will involve with this new regimen? And then the second question, second part of the question is, you know, have you enrolled any patient with such regimen, yeah? Yeah, so the study is designed so that any standard regimen that's used in frontline currently, if you are MRD positive at the end of that regimen, then you're eligible for alpha-3. So really, in practical fact right now, that means R-CHOP and polituzumab RCHP. Those are really the only two approved regimens. Of course, there's variants of R-ChOP out there, and those are eligible too. So there's no bispecific patients that have come into the study. However, one could imagine that if such a regimen is approved and the study is still enrolling and they were MRD positive at the end of that regimen, they would be eligible. So that is viewed as how this will work in the end because one of the key features of Alpha-3 is that it doesn't really matter what happens up front. If you are MRD positive at the end, it means that whatever you got didn't really work. It didn't work all the way. And so that's where the semicell could add value. So we don't much care which regimen these patients receive in the frontline setting. Now, the other question that you asked is, is that going to change the MRD-positive dynamics? I would say it would, based on the hazard ratio. Of course, we haven't seen any of the other data. We don't know what the PFS actually was. we don't know what the safety profile looked like. So there's a lot we still don't know about that. But we did expect that it was going to be a positive outcome. Those are powerful, potent regimens. However, they are toxic and complex and significantly more toxic than R-CHOP or polituzumab, RCHP. So based on conversations we've had, as well as some quantitative market research, we actually feel like the uptake of these regimens is going to be fairly restricted and really for select patients at select centers. And one of the realities that we're grappling with with Alpha-3 is that almost all of these patients who are newly diagnosed with lymphoma are diagnosed in the community and treated in the committee. And these regimens that are toxic and complex really are not community-friendly regimens. So they're probably going to be for patients who are referred in for some reason. They have very high-risk disease or they're super sick. When they're first diagnosed, they'll get sent to a referral center. Maybe those patients will get an EPCOR-based regimen. But for the rank and file, they're going to continue to get Polar CHIP and RCHOP. And so we expect, even once these regimens are approved, assuming they do get approved, that it's going to have a pretty minimal impact on the overall MRD positivity, probably about 5% to 10% on the Overall Rate across the board of MRD Positivity. Got it. Okay, great. And for the MRD testing, do you see it will evolve into a greater adoption? And then how Alpha 3 data will change the landscape as well? Another great question, and I think really drives it, the dynamic nature of this space. So we've actually done two rounds of market research. One was a qualitative round, which was about 30 physicians, and then the more recent one was about 150 physicians. And just one snippet of information from that research is that when we first asked the 30 physicians how frequently were they using MRD, that number was about 20%. And then when we asked the 150, it was closer to 40%. So even in the few months between those two rounds of research, again, it's not the entire story about the dynamics of the field right now, But we're seeing already substantive uptake in MRD, and that's also corroborated in the quarterly calls by the MRD companies saying that they're just seeing really rapid uptake of MRD specifically in lymphoma. Your question around will the availability of semicell change those dynamics, 100 percent. In fact, we actually tested that in our research, and it is the current lack of a treatment decision that you can make based on a positive result, which is keeping some physicians from ordering the test in the first place. Everyone orders the test now. Who orders it? Because they hope it's going to come back negative, because that's great news for the patients, very good prognostic information. The problem is if it comes back positive, then that's a very difficult conversation that you have with the patient because you don't have anything to offer them. So SemaCell will solve that if it's approved. Yeah, awesome. All right, great. And then in terms of the Office 3 enrollment geography or diversity of the patient, how many of them are U.S., global, Asian? And then another angle is the academic versus the community. So what's the balance of the enrollment so far? Yeah, so last update I think we said we have over 85 sites globally. That includes the U.S., Canada, Australia, and South Korea. So I can say now that the Asia-Pac region is fully onboarded. All the sites that we had selected are now open to enrollment, and they've done a really stellar job at coming online very rapidly. So they're screening patients extremely efficiently and enrolling patients very well, so we've been quite pleased to see that. The next goal that we've set for ourselves is to have approximately 100 sites online by the end of this calendar year. And then Europe is going to be opening in the first half of next year. So we'll have a lot more news as time goes on around the final configuration and footprint of the study. As for the breakdown of community versus academic, traditionally we've said it's about 50-50. I do think it's probably a little bit more than 50% academic now as some of the sites in abroad have come on. There's not really the same bifurcation of care between community and academia in Korea and Australia as there is in the U.S. So all of those sites really are considered to be more academic sites. So we're starting to see a little bit of a shift towards a more academic balance, but that's long been expected. And we're still seeing terrific activity from the community sites that are on board. Yeah, got it. But in terms of U.S. and then maybe not the Canada, those kind of Western countries, they are still relatively 50-50. Yeah, it's certainly in the U.C. We have a lot of community practices in the US, and they were early. They saw the value of this. This is, in many cases, the first opportunity they have to offer CAR-T to their patient population. So the value proposition of the Alpha-3 trial and of semicell in consolidation has only grown in appeal to those practices. So we're seeing super engagement from those practices here in the States. Yeah, because as you said earlier, a lot of patients are managing in the community, so you want to make sure they can use this. Correct. The overarching goal of this trial is to actually provide access to CAR T to patients who historically do not have access. So it's a stat that I often bring up, which is only about 15% to 20% of patients in the United States who could benefit from a CAR T are ever offered a CART, ever receive a CAR-T. that's a really terrible state of affairs and one where I think a disruptive technology like SemaCell and disruptive design like Alpha-3 can really solve that problem because as we're validating in the study, we can actually deliver these products where patients receive their care rather than making the patients go to where the care is available. Yeah, got it. Last question related to the Sema-Cell. You're definitely the leader and the first one, maybe the only one still doing this setting, first line consolidation. Any other potential allergenic CAR T on your radar can be also applicable to this setting or any plan you know? We don't know, but maybe you know. I think there are some investigator-sponsored studies that are beginning to crop up that are now public, and so we're seeing this. I think that is highly validating for our idea here of frontline consolidation. So we welcome the company. We are, as you point out, well ahead of everybody else, And that's because we saw this field developing back in 2023 based on the strength of that early data from MRD and realized that there was a big opportunity here. So we moved quickly, and I think that is a tremendous benefit for us. And so even if we do see some early phase studies coming online, it's certainly not something that we think is going to threaten us in a commercial context. Excellent. Okay, we should talk about this autoimmune as well. And as you said, you are the only CD19 and CD70 in the autoimmune disease at the CAR-T. So recently we saw the data from ICR, which is pretty interesting. And then you do see a lot of the good clinical activity. My question is, I think I may have asked you that before, but I just want to put that on the record. The correlation between the B-cell depletion and the clinical activity, how do you explain that? I know maybe it's also related to CD70, but also maybe related to resell. We just don't know the threshold to kind of reset the pathogenic kind of B-cell. So tell us a little bit more about the correlation. Yeah, I think what our data really highlights is that there's still a lot that we as a field don't understand about what an immune reset is. And I think that in the early days, it was quite easy to look at peripheral B- cells and seeing them go to zero for 28 days. that was all the explanation we needed to see these profound and durable responses in patients who received CAR-T for autoimmune disease. It's not only our data, by the way, that is starting to provide a little bit of hints that maybe there's more to this story. We see peer-reviewed publications coming out now that is zeroing in on specific subpopulations of B cells that may be driving the pathogenesis in these indications. So I think there's still a lot more for us to learn. And I will point out, it's not like we saw no change in the B cells in the no-lympho depletion arm. We did see about a 30% to 40% reduction. It tended to be transient, but clearly there is some activity there. And you also brought up the CD70 component. So one of the key aspects and one ofthe reasons that we included the CD7 is because we know that this is a key player in the formation of immune synapses, in the activation of T and B lymphocytes, and it's also expressed on antigen-presenting cells. So it is increasingly likely, as we learn more about this molecule and its central role in the activation of an immune response, that modulation of B and T cells that express CD70 is likely to have a disproportionate effect on the outcome of the disorder. Now, this is still early days. There's a lot for us to learn. We have lots of preliminary correlative work that we're working on internally right now that wasn't quite ready for prime time in the poster, so we didn't include it, but we look forward to developing that storyline in the coming months. But at the end of the day, taking a step back, you look at our data, and these patients are incontrovertibly getting better, having significant improvements in their symptoms, and are very difficult to treat disease of diffuse cutaneous scleroderma, and we're able to do it without imparting significant immunosuppression in these patients that would come with the flu-sci regimen. Yeah, got it. Okay. Just I know you have a lot of internal data that have not yet released. Would that be including the CAR-T expansion? Because at least that's another PK or slash kind of PD you can... Yeah, that's a very interesting area, Roger. Of course, the peripheral blood compartment is a very easy thing to assess and an easy thing to measure. Where I think the field has maybe sort of not pushed as hard as we should is we check one spot, we get what we think we're supposed to get, and then we move on. And so we have already learned in the field of autoimmune CAR T that we don't see the same degree of expansion and persistence that we see in oncology, that most of the action probably is in the tissues, not in the peripheral blood. So we started at very low doses, as you recall. So the first doses that we started out was 20 million cells flat dose. Then we went to 40 and then 80. And then we also disclosed last week that the next dose level is 160 million cells. We are still well below our peer companies in terms of the overall level of dose, particularly as it applies to allogeneic. So that story is obviously something that we're watching quite keenly and, again, looking for the areas within the body that could be generating the right PK, cellular connect, cellular activity, that would lead to the observations that we are making at the bedside. Yeah, got it. All right, and then you mentioned you'll keep those escalating, and next is the 160, I think, and 320 are also planned. So what will be the next steps, right? So you're going to continue to escalate, we're goingto see data, and then when you'regoing to start to do those expansions, do you need more full data from the escalation before you can move into the expansion? So, yeah, the study was written with great flexibility, so we can actually expand any cohort at any point. once that cohort and that regimen has been deemed safe to proceed based on an independent safety review team who looks at all the data. So we have ultimate flexibility about which cohorts we want to expand versus continuing to dose escalate. We can actually do both at the same time. So right now, internally, we're evaluating the data that we shared at ACR as well as additional data that has accumulated since the data cut that went into the ACR presentation. And so we're starting to make some strategic decisions about what to do with the study. I'll call out specifically whether we continue to dose with the flu-sci regimen. I think some of the events in recent weeks around potential flu-darabing toxicity in CAR-T and autoimmune has sort of certainly put that in perspective, whether that's the right risk benefit for those patients. And then, of course, we also need to decide, Are we going to continue to enroll all three indications that are currently eligible for the basket study? That's lupus, myositis, and scleroderma. So we have some near-term decisions about how to refine and tailor the development strategy, including whether and what dose we expand. So look for some news updates early in the new year as we advance that program. Got it. those conditioning regimen indication so they all TBD in the next kind of step and then that you will potentially expand this to a correct yeah and ultimately here of course we're looking to build an evidence base that would support a phase two that's exactly my last question so how and when you're gonna move into the pivoter because the car T cell therapy it's a great in clinical but eventually you translate that into the business so when we cannot see that yeah so I would say you know look to 2027 for those updates and and you know the study one thing that has been great about this trial since the day we opened it is that we have had no problems enrolling it we enrolled those 18 patients that we featured at the ACR in about 10 months from from the first patient enrolled until the data cut we've had now several additional patients already enroll in the trial so and we've got a waiting list of patients get ready to come in so So, we have kind of the resources to continue to develop this asset and make very informed decisions. So, I don't want to get too far ahead of myself about when we might make those decisions, but rest assured it will come in the next few months. MR. Excellent. Thank you so much, Zach. MR. Thank you. MR. Thank you, everyone.
- Company
- ALLOGENE THERAPEUTICS INC
- Keywords
- ALLOGENE THERAPEUTICS INC